Core Viewpoint - The company, Global Medical (02666), has received approval from the China Securities Regulatory Commission to publicly issue a maximum of RMB 2 billion in domestic renewable corporate bonds aimed at qualified investors, with a remaining quota of RMB 1.2 billion as of the announcement date [1] Group 1: Bond Issuance Details - The bond will be issued in tranches, with the total principal amount not exceeding RMB 850 million [1] - The basic term of the corporate bond is set at 3 years, with the issuer having the option to extend the term by one repricing cycle or fully redeem the bond at the end of the basic term and each repricing cycle [1] - The bond includes options for the issuer to extend the term, defer interest payments, and redeem the bond [1] Group 2: Interest Rate Structure - The interest rate for the first cycle will remain fixed and will be determined through a book-building process at the time of subscription [1] - The coupon rate is set as the initial benchmark rate plus an initial spread, with subsequent cycles resetting the coupon rate to the current benchmark rate plus the initial spread plus an additional 300 basis points [1] Group 3: Use of Proceeds - The net proceeds from the bond issuance will be used by the issuer to supplement operational funds [1]

鑫科材料8月5日公告，公司当天收到上海证券交易所出具的《关于受理安徽鑫科新材料股份有限公司非 公开发行公司债券挂牌转让申请的通知》。上交所对公司报送的非公开发行公司债券并挂牌转让的申请 文件进行了核对，并予以受理。但公司本次非公开发行公司债券尚需获得上交所无异议函后方可实施， 最终能否取得该函件及取得时间尚存在不确定性。 ...

鑫科材料公告，公司于2025年8月5日收到上海证券交易所出具的《关于受理安徽鑫科新材料股份有限公 司非公开发行公司债券挂牌转让申请的通知》。上交所对公司报送的非公开发行公司债券并挂牌转让的 申请文件进行了核对，并予以受理。但公司本次非公开发行公司债券尚需获得上交所无异议函后方可实 施，最终能否取得该函件及取得时间尚存在不确定性。 ...

中州证券(01375)发布公告，公司于近日收到中国证券监督管理委员会《关于同意中原证券（601375） 股份有限公司向专业投资者公开发行公司债券注册的批复》(证监许可〔2025〕1556号)，批复内容如 下：一、同意你公司向专业投资者公开发行面值总额不超过25亿元公司债券的注册申请。二、本次发行 公司债券应严格按照报送上海证券交易所的募集说明书进行。三、本批复自同意注册之日起24个月内有 效，你公司在注册有效期内可以分期发行公司债券。 ...

Group 1 - The company plans to apply for the registration and issuance of corporate bonds not exceeding RMB 2 billion, with the final amount subject to regulatory approval [1][10][29] - The bond term will not exceed 5 years and may consist of a single term or a mix of different terms, determined based on market conditions and funding needs [1][10][30] - The funds raised will be used for repaying bank loans, supplementing working capital, and other purposes compliant with national laws and regulations [1][10][30] Group 2 - The resolution for the bond issuance is valid for 36 months from the date of approval by the shareholders' meeting [2][12][31] - The board of directors is authorized to handle all matters related to the bond issuance, including determining the issuance timing, terms, and other relevant details [3][13][32] - The bond issuance proposal has been approved by both the board of directors and the supervisory board, pending final approval from the shareholders' meeting [6][18][29] Group 3 - The company will hold the second extraordinary shareholders' meeting on August 28, 2025, to discuss the bond issuance and other related matters [41][42][24] - The meeting will utilize both on-site and online voting methods, ensuring participation from shareholders [42][43][45] - The company has established a bond information disclosure management system to ensure compliance and transparency in the bond issuance process [37][39]

Group 1 - The company intends to apply for the registration and issuance of corporate bonds to expand financing channels and optimize its financing structure [1][2] - The final registration scale will be determined based on the approval from regulatory authorities, and the issuance scale will be adjusted according to the company's actual funding needs and market conditions [1][2] - The bond issuance may include various types and maturities, and the company will decide on the specific terms and amounts based on market conditions [1][2] Group 2 - The board of directors seeks authorization from the shareholders' meeting to handle all matters related to the bond issuance, including the issuance timing, terms, rates, and other relevant details [2] - The authorization is valid from the date of approval by the shareholders' meeting until the completion of the authorized matters [2] - The proposal for the bond registration and issuance must be approved at the company's second extraordinary shareholders' meeting in 2025 [2][3]

Group 1 - The company, Huatai Securities, announced the issuance of a short-term corporate bond (the sixth phase) aimed at professional investors, with a maturity of 7 months (212 days) [1] - The final coupon rate for this bond issuance was determined to be 1.63% based on the results of inquiries from professional institutional investors and negotiations between the issuer and the lead underwriter [1]

格隆汇8月1日｜牧原股份公告，公司于近日收到中国证券监督管理委员会于2025年7月25日出具的《关 于同意牧原食品股份有限公司向专业投资者公开发行公司债券注册的批复》，证监会同意公司向专业投 资者公开发行面值总额不超过50亿元公司债券的注册申请。批复自同意注册之日起24个月内有效，公司 在注册有效期内可以分期发行公司债券。 ...

国信证券股份有限公司 2025 年面向专业投资者公开发行公司债券（第五期）募集说明书 声明 发行人将及时、公平地履行信息披露义务，发行人及其全体董事、监事、高 级管理人员或履行同等职责的人员保证募集说明书信息披露的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏。 主承销商已对募集说明书进行了核查，确认不存在虚假记载、误导性陈述和 重大遗漏，并对其真实性、准确性和完整性承担相应的法律责任。 发行人承诺在本期债券发行环节，不直接或者间接认购自己发行的债券。债 券发行的利率或者价格应当以询价、协议定价等方式确定，发行人不会操纵发行 定价、暗箱操作，不以代持、信托等方式谋取不正当利益或向其他相关利益主体 输送利益，不直接或通过其他利益相关方向参与认购的投资者提供财务资助、变 相返费，不会出于利益交换的目的通过关联金融机构相互持有彼此发行的债券， 不实施其他违反公平竞争、破坏市场秩序等行为。 发行人如有董事、监事、高级管理人员、持股比例超过 5%的股东及其他关 联方参与本期债券认购，发行人将在发行结果公告中就相关认购情况进行披露。 中国证券监督管理委员会、深圳证券交易所对债券发行的注册或审核，不代 表对债券的 ...

国信证券股份有限公司 （第五期） 发行公告 发行人 牵头主承销商、债券受托管理人 住所：北京市丰台区西营街 8 号院 1 号楼 7 至 18 层 101 联席主承销商 住所：深圳市福田区福田街道福华一路 119 住所：广东省深圳市福田区福田街道金田路 号安信金融大厦 2026 号能源大厦南塔楼 10-19 层 住所：深圳市福田区福田街道益田路 5023 号 平安金融中心 B 座第 22-25 层 本公司及其董事、监事、高级管理人员保证公告内容真实、准确和完整，并对公告 中的虚假记载、误导性陈述或者重大遗漏承担责任。 重要事项提示 获得中国证券监督管理委员会证监许可[2024]1722 号文，可向专业投资者公开发行面值 总额不超过 200 亿元的公司债券（以下简称"本次债券"）。 发行人本次债券采取分期发行的方式，"国信证券股份有限公司 2025 年面向专业投 资者公开发行公司债券（第五期）"（以下简称"本期债券"）为本次债券项下第六期， 发行规模为不超过人民币 30 亿元（含 30 亿元），债券简称"25 国证 07"。 者及专业投资者中的个人投资者不得参与发行认购。本期债券上市后将被实施投资者适 当性管理， ...